Teladoc Health Inc. (TDOC) shares are soaring 5.12% in pre-market trading on Friday, following the company's announcement of better-than-expected preliminary third-quarter revenue and reaffirmed full-year guidance. The telehealth provider reported preliminary Q3 revenue of $626.4 million, surpassing analysts' estimates of $625.9 million.

Despite the announced departure of Chief Financial Officer Mala Murthy, effective November 21, investors seem to be focusing on the company's strong financial performance. Teladoc also reiterated its 2025 revenue forecast range of $2.50 billion to $2.55 billion, in line with analyst expectations of $2.52 billion.

The positive sentiment is further bolstered by analyst actions. Bank of America raised its price target on Teladoc to $9 from $8.50, while maintaining a Neutral rating. Canaccord Genuity analyst Richard Close reiterated a Buy rating with a $12 price target, citing the company's potential for growth. These developments suggest that despite leadership changes, Teladoc's business fundamentals remain strong, driving investor confidence and the stock's upward movement.